Astellas Pharma ROA - Return on Assets 2012-2024 | ALPMY

Astellas Pharma return on assets for the quarter ending June 30, 2024 was 3.12.

  • Astellas Pharma average return on assets for 2023 was 5.83, a 22.68% decline from 2022.
  • Astellas Pharma average return on assets for 2022 was 7.54, a 19.44% decline from 2021.
  • Astellas Pharma average return on assets for 2021 was 9.36, a 9.65% decline from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

Astellas Pharma ROA - Return on Assets 2012-2024 | ALPMY

  • Astellas Pharma average return on assets for 2023 was 5.83, a 22.68% decline from 2022.
  • Astellas Pharma average return on assets for 2022 was 7.54, a 19.44% decline from 2021.
  • Astellas Pharma average return on assets for 2021 was 9.36, a 9.65% decline from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.7B
Takeda Pharmaceutical (TAK)$47.3B
Merck (MKGAF)$23.7B
Summit Therapeutics (SMMT)$19B
Sandoz Group AG (SDZNY)$17.5B
United Therapeutics (UTHR)$15.4B
Shionogi (SGIOY)$13.3B
Neurocrine Biosciences (NBIX)$12.4B
Catalent (CTLT)$11B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.3B
Jazz Pharmaceuticals (JAZZ)$6.9B
Ionis Pharmaceuticals (IONS)$6.1B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.1B
Crinetics Pharmaceuticals (CRNX)$4.2B
Corcept Therapeutics (CORT)$4.1B
Dyne Therapeutics (DYN)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
PTC Therapeutics (PTCT)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.5B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Harrow (HROW)$1.5B
Cassava Sciences (SAVA)$1.5B
Ardelyx (ARDX)$1.4B